B. Harish Kumar

B. Harish Kumar

Auto-generated profile, based on publicly available information

B. Harish Kumar

Department of Applied Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad-500 007, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
VEVignesh Balaji E
Vignesh Balaji E
SSSairaj Satarker
Sairaj Satarker
BKB. Harish Kumar
B. Harish Kumar
SPSamyak Pandey
Samyak Pandey
SBSumit Raosaheb Birangal
Sumit Raosaheb Birangal
KPK. Sreedhara Ranganath Pai
K. Sreedhara Ranganath Pai
Glioblastoma (GBM) is an aggressive malignant type of brain tumor. Targeting one single intracellular pathway might not alleviate the disease, rather it activates the other molecular pathways that lead to the worsening of the disease condition. Therefore, in this study, we attempted to target both isocitrate dehydrogenase 1 (IDH1) and IDH2, which are one of the most commonly mutated proteins in GBM and other cancer types. Here, standard precision and extra precision docking, IFD, MM-GBSA, QikProp, and molecular dynamics (MD) simulation were performed to identify the potential dual inhibitor for IDH1 and IDH2 from the enamine database containing 59,161 ligands. Upon docking the ligands with IDH1 (PDB: 6VEI) and IDH2 (PDB: 6VFZ), the top eight ligands were selected, based on the XP Glide score. These ligands produced favourable MMGBSA scores and ADME characteristics. Finally, the top four ligands 12953, 44825, 51295, and 53210 were subjected to MD analysis. Interestingly, 53210 showed maximum interaction with Gln 277 for 99% in IDH1 and Gln 316 for 100% in IDH2, which are the crucial amino acids for the inhibitory function of IDH1 and IDH2 to target GBM. Therefore, the present study attempts to identify the novel molecules which could possess a pan-inhibitory action on both IDH1 and IDH that could be crucial in the management of GBM. Yet further evaluation involving in vitro and in vivo studies is warranted to support the data in our current study.Communicated by Ramaswamy H. Sarma.

22 September 2025 in RSC Advances
Verified
Journal Article
Open access
PDF file
MKMommuleti Pradeep Kumar
Mommuleti Pradeep Kumar
TSTukki Sarkar
Tukki Sarkar
VPVemavarapu Durga Prasad
Vemavarapu Durga Prasad
NSNidhi Sharma
Nidhi Sharma
HBHarish Kumar B.
Harish Kumar B.
BBBathini Nagendra Babu
Bathini Nagendra Babu
Ru( ii )-catalyzed synthesis of 1 H -pyrido[3,4- b ]indol-1-one hybrids via annulation of indole amides with ynones yielded compound 9c, showing selective cytotoxicity toward MDA-MB-231 cells and moderate EGFR affinity, indicating therapeutic promise.

1 January 2021
Verified
Book Chapter
Closed access
SMSuman Manandhar
Suman Manandhar
RSRunali Sankhe
Runali Sankhe
BKB. Harish Kumar
B. Harish Kumar
KPK. Sreedhara Ranganath Pai
K. Sreedhara Ranganath Pai